CompoAtlas

MOONSTRUCK II (sandìa loca)

Food supplement declared in France, decision dated 23 May 2026

MOONSTRUCK II (sandìa loca) is a food supplement declared in France. Status: déclaré en France, commercialisation possible : l'administration ne s'est pas opposée à la déclaration (ce n'est ni une autorisation ni une évaluation de sécurité). 3 rules of use apply to its ingredients (limits and warnings).

Brand
not provided
Food business operator placing the product on the market
Beaufit Sl
Status
Déclaré en France, commercialisation possible : l'administration ne s'est pas opposée à la déclaration (ce n'est ni une autorisation ni une évaluation de sécurité)
Form
Poudre
Daily dose
9,5 g (1/2 cuillère doseuse) par jour
Directions for use
Diluer 9,5 g (1/2 cuillère doseuse)
Intended populations
Hommes et femmes de 18 ans et plus
Not recommended for (according to the manufacturer)
Adolescents (moins de 18 ans), Femmes allaitantes, Autre : N/A, Femmes enceintes, Sous antidépresseurs, Sous antidiabétiques
Objectives stated by the manufacturer (these are not authorised claims)
Autre : N/A
Flavourings
SANDÍA LOCA

Declaration 365769, procedure Article 15. Compl'Alim, food supplement declarations (France), retrieved 23 October 2026.

Regulatory points

Declared composition

Plants

PlantPartPreparationPer day
Beta vulgaris L.RacineExtrait sec aqueux975 mg
Vitis vinifera L.PépinExtrait sec aqueux25 mg
Camellia sinensis (L.) KuntzeFeuilleExtrait sec aqueux25 mg
Panax ginseng C.A.Mey.RacineExtrait sec aqueux25 mg
Ginkgo biloba L.FeuilleExtrait sec aqueux25 mg

Substances

NamePer day
bêta-alanine1,500 mg
caféine0.5 mg

Other active ingredients

NamePer day
L-citrulline malatenot declared
L-Arginine-alpha-cétoglutaratenot declared

Additives

E551, E950, E955, E330

List from the declaration, administrative decision dated (Compl'Alim, food supplement declarations (France)).

Has the product changed? Photograph the packaging.

Label warnings

Ne pas laisser à la portee des jeunes enfants. Consultez votre medecin en cas de prise simultanee d'anticoagulants. Deconseille aux personnes sous traitement antidepresseur ou antidiabetique, en cas d'epilepsie et en cas d'acte interventionnel invasif programme. En cas de traitements medicamentaux, demander conseille à un professionnel de sante. Ne pas prendre plus de 800 mg/dose journalière d'epigallocatechine-3-gallate. Ne doit pas être consomme si vous prenez le meme jour d'autres produits contenant du the vert. Ne doit pas être consomme par les femmes enceintes ou allaitantes et par les enfants de moins de 18 ans. Ne doit pas etre consomme à jeun. Reserve à l'adulte.

This information reproduces the manufacturer's declaration to the administration (DGAL). It does not say whether the product is effective and does not replace advice from a doctor or pharmacist, particularly during pregnancy or when taking medication.

Official warnings (Health Canada)

Health Canada publishes warnings on these ingredients:

  • Panax ginseng C.A.Mey.
    Read the warning, when it applies and the studies cited

    PANAX GINSENG

    Route of administration: Oral

    Cautions and warnings

    Ask a health care practitioner/health care provider/health care professional/doctor/physician before use if you are pregnant or breastfeeding.

    Ask a health care practitioner/health care provider/health care professional/doctor/physician before use if you have diabetes (Brinker 2010; Vuksan et al. 2008; Seely et al. 2008; Sievenpiper et al. 2006; ESCOP 2003; Tetsutani et al. 2000; Sotaniemi et al. 1995; Chin 1991).

    8 studies cited in the text have no matching reference in the monograph (see the anomalies listed on the sources page).

    Ask a health care practitioner/health care provider/health care professional/doctor/physician before use if you are taking antidepressant medication, blood thinners or digoxin (Brinker 2010; Lee et al. 2008a; Dasgupta and Reyes 2005; Janetzki and Morreale 1997; Gonzalez-Seijo et al. 1995; Shader and Greenblatt 1988; Jones and Runikis 1987; Shader and Greenblatt 1985).

    8 studies cited in the text have no matching reference in the monograph (see the anomalies listed on the sources page).

    Contraindications

    Condition of application: Traditional Chinese Medicine.

    Do not use in cases of yin deficiency with heat signs, heat excess, or in the absence of significant qi deficiency (Bensky et al. 2004).

    1 study cited in the text has no matching reference in the monograph (see the anomalies listed on the sources page).

    Known adverse reactions

    Stop use and ask a health care practitioner/health care provider/health care professional/doctor/physician if you experience insomnia, anxiety or headaches (Lee et al. 2008b; Vuksan et al 2008; de Andrade et al.2007; Sievenpiper et al. 2006; Coon and Ernst 2002; Ellis and Reddy 2002; Scaglione et al. 2001; Siegel 1979).

    8 studies cited in the text have no matching reference in the monograph (see the anomalies listed on the sources page).

    Health Canada monograph dated 27 June 2025

  • Ginkgo biloba L.
    Read the warning, when it applies and the studies cited

    GINKGO - GINKGO BILOBA

    Route of administration: Oral

    Cautions and warnings

    Ask a health care practitioner/health care provider/health care professional/doctor/physician before use if you are pregnant or breastfeeding (Blumenthal et al. 2000; WHO 1999).

    2 studies cited in the text have no matching reference in the monograph (see the anomalies listed on the sources page).

    Ask a health care practitioner/health care provider/health care professional/doctor/physician before use if you are taking diabetes, high blood pressure or seizure medications (Brinker 2010).

    1 study cited in the text has no matching reference in the monograph (see the anomalies listed on the sources page).

    Contraindications

    Do not use if you are having a surgery (Gardner and McGuffin 2013).

    1 study cited in the text has no matching reference in the monograph (see the anomalies listed on the sources page).

    Do not use if you are taking blood thinners or other health products that affect blood coagulation (Gardner and McGuffin 2013; Brinker 2010; Bent 2005).

    3 studies cited in the text have no matching reference in the monograph (see the anomalies listed on the sources page).

    Health Canada monograph dated 25 July 2025

  • caféine
    Read the warning, when it applies and the studies cited

    CAFFEINE

    Route of administration: Oral (Higdon and Frei 2006)

    Cautions and warnings

    Applies to products providing 100 mg to 400 mg caffeine, per day1.

    Ask a health care practitioner/health care provider/health care professional/doctor/physician before use if you have high blood pressure or glaucoma (Cornelis and El-Sohemy 2007, Chandrasekaran et al. 2005, Noordzij et al. 2005, Avisar et al. 2002, Arya et al. 2000, Jee et al. 1999, Creighton and Stanton 1990).

    7 studies cited in the text have no matching reference in the monograph (see the anomalies listed on the sources page).

    1Note: This statement is also required at subtherapeutic quantities for products providing 40 mg or more caffeine per day from all sources for Class II and III applications.

    Applies to products providing more than 300 mg caffeine, per day.

    Ask a health care practitioner/health care provider/health care professional/doctor/physician before use if you are pregnant, breastfeeding, or attempting to conceive (Nawrot et al. 2003).

    1 study cited in the text has no matching reference in the monograph (see the anomalies listed on the sources page).

    Applies to products providing 400 mg or more caffeine, per day.

    When using this product avoid taking other health products, foods or beverages that contain caffeine and/or increase blood pressure (FDA 2023; Bui et al. 2006; Bouchard et al. 2005; Haller et al. 2005; NIH 2004; Berardi et al. 2002; Vahedi et al. 2000; Zimmerman 1992).

    8 studies cited in the text have no matching reference in the monograph (see the anomalies listed on the sources page).

    Contraindications

    Applies to products providing more than 400 mg caffeine per day.

    Do not use if you have high blood pressure or glaucoma (Cornelis and El-Sohemy 2007, Chandrasekaran et al. 2005, Noordzij et al. 2005, Avisar et al. 2002, Arya et al. 2000, Jee et al. 1999, Creighton and Stanton 1990).

    7 studies cited in the text have no matching reference in the monograph (see the anomalies listed on the sources page).

    Known adverse reactions

    Condition of application: All products.

    Stop use and ask a health care practitioner/health care provider/health care professional/doctor/physician if hypersensitivity/allergy occurs (Infante et al. 2003; Hinrichs et al. 2002).

    2 studies cited in the text have no matching reference in the monograph (see the anomalies listed on the sources page).

    Applies to products providing 200 mg or more caffeine, per day.

    Stop use and ask a health care practitioner/health care provider/health care professional/doctor/physician if symptoms such as chest pain and irregular heartbeat occur (Higgins and Babu 2013).

    1 study cited in the text has no matching reference in the monograph (see the anomalies listed on the sources page).

    Applies to products providing more than 400 mg caffeine, per day.

    Stop use and ask a health care practitioner/health care provider/health care professional/doctor/physician if nervousness, anxiety, insomnia, tremor and/or headache occur (IOM 2001, Zhang 2001, Sawynok 1995).

    3 studies cited in the text have no matching reference in the monograph (see the anomalies listed on the sources page).

    Condition of application: All products except those making a diuretic claim1.

    When using this product diuretic effect may occur.

    1Note: This statement is also required at subtherapeutic quantities for products providing 40 mg or more caffeine per day from all sources for Class II and III applications.

    Health Canada monograph dated 19 December 2025

They concern the ingredient, not this product or its dose. They do not replace medical advice.

Other declarations with the same name

In France, every company that markets a supplement declares it, so one product can have several declarations (new formula, another distributor, an older declaration withdrawn). Each line compares the declared composition with this page.

Is something on this product wrong or out of date, whether you are a reader or the brand? Write to contact@compoatlas.com: every correction is published in the corrections log.

Enter to analyse, Shift+Enter for a new line